February 12, 2024 · Form 4 insider transaction
GILEAD SCIENCES, INC. sold 7,746,139 shares of KYTX at $0.00 per share, a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 1 day after the transaction.
The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date.; Reflects a 1-for-4.5511 reverse stock split, which became effective on January 30, 2024.